We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Federal Circuit Panel Invalidates The Medicines Co.’s Angiomax Patents
Federal Circuit Panel Invalidates The Medicines Co.’s Angiomax Patents
A panel of judges from the Federal Circuit Court of Appeals has ruled that two of The Medicines Company’s patents for its anticlotting drug Angiomax are invalid — a win for Hospira, which is planning a generic version of the treatment.